The effects of the dietary polyphenol resveratrol on human healthy aging and lifespan

Epigenetics

Volumn 6, Issue 7, 2011, Pages 870-874

  Fernández, Agustín F ^a   Fraga, Mario F ^a,b  

^a DEPARTAMENTO DE BIOQUÍMICA Y BIOLOGÍA MOLECULAR   (Spain)

^b CENTRO NACIONAL DE BIOTECNOLOGÍA   (Spain)

Author keywords

Aging; Cancer; Lifespan; Resveratrol; SIRT1

Indexed keywords

HYDROXYMETHYLGLUTARYL COENZYME A REDUCTASE KINASE; RESVERATROL; SIRTUIN 1;

AGING; ANTIINFLAMMATORY ACTIVITY; ANTINEOPLASTIC ACTIVITY; ANTIOXIDANT ACTIVITY; ANTIVIRAL ACTIVITY; ARTICLE; ATHEROSCLEROSIS; CALORIC RESTRICTION; CANCER CELL CULTURE; CANCER MODEL; CELL DIFFERENTIATION; DIABETES MELLITUS; DIET SUPPLEMENTATION; DRUG MECHANISM; DRUG METABOLISM; ENZYME ACTIVATION; HUMAN; HYPERTENSION; ISCHEMIA; LIFESPAN; NEUROPROTECTION; NONHUMAN; OBESITY; SKIN CANCER; STEM CELL; THROMBOSIS;

MUS;

EID: 79960137178     PISSN: 15592294     EISSN: 15592308     Source Type: Journal    
DOI: 10.4161/epi.6.7.16499     Document Type: Article

References (86)

1. Aguilera O, Fernandez AF, Munoz A, Fraga MF. Epigenetics and environment: a complex relationship. J Appl Physiol 2010; 109:243-51.
2. Fraga MF. Genetic and epigenetic regulation of aging. Curr Opin Immunol 2009; 21:446-53.
3. Calvanese V, Lara E, Kahn A, Fraga MF. The role of epigenetics in aging and age-related diseases. Ageing Res Rev 2009; 8:268-76.
4. Fraga MF, Agrelo R, Esteller M. Cross-talk between aging and cancer: the epigenetic language. Ann NY Acad Sci 2007; 1100:60-74.
5. Peysselon F, Ricard-Blum S. Understanding the biology of aging with interaction networks. Maturitas 2011; 69:126-30.
6. Urdinguio RG, Sanchez-Mut JV, Esteller M. Epigenetic mechanisms in neurological diseases: genes, syndromes and therapies. Lancet Neurol 2009; 8:1056-72.
7. Kudlow BA, Kennedy BK, Monnat RJ Jr. Werner and Hutchinson-Gilford progeria syndromes: mechanistic basis of human progeroid diseases. Nat Rev Mol Cell Biol 2007; 8:394-404.
8. Martin GM, Bergman A, Barzilai N. Genetic determinants of human health span and life span: progress and new opportunities. PLoS Genet 2007; 3:125.
9. Kuningas M, Mooijaart SP, van Heemst D, Zwaan BJ, Slagboom PE, Westendorp RG. Genes encoding longevity: from model organisms to humans. Aging Cell 2008; 7:270-80.
10. Fraga MF, Esteller M. Epigenetics and aging: the targets and the marks. Trends Genet 2007; 23:413-8.
11. Attig L, Gabory A, Junien C. Early nutrition and epigenetic programming: chasing shadows. Curr Opin Clin Nutr Metab Care 2010; 13:284-93.
12. Nascimento AF, Luvizotto RA, Leopoldo AS, Lima-Leopoldo AP, Seiva FR, Justulin LA Jr, et al. Longterm high-fat diet-induced obesity decreases the cardiac leptin receptor without apparent lipotoxicity. Life Sci 2011; 88:1031-8.
13. Ueda Y, Wang MF, Irei AV, Sarukura N, Sakai T, Hsu TF. Effect of dietary lipids on longevity and memory in the SAMP8 mice. J Nutr Sci Vitaminol (Tokyo) 2011; 57:36-41.
14. Alappat L, Awad AB. Curcumin and obesity: evidence and mechanisms. Nutr Rev 2010; 68:729-38.
15. Li S, Micheletti R. Role of diet in rheumatic disease. Rheum Dis Clin North Am 2011; 37:119-33.
16. Obrenovich ME, Nair NG, Beyaz A, Aliev G, Reddy VP. The role of polyphenolic antioxidants in health, disease and aging. Rejuvenation Res 2010; 13:631-43.
17. Solfrizzi V, Frisardi V, Seripa D, Capurso C, Vendemiale G, Pilotto A, et al. Dietary patterns and protection against Alzheimer disease and cognitive decline. Arch Neurol 2010; 67:1285-6.
18. Spence JD, Jenkins DJ, Davignon J. Dietary cholesterol and egg yolks: not for patients at risk of vascular disease. Can J Cardiol 2010; 26:336-9.
19. Harikumar KB, Aggarwal BB. Resveratrol: a multitargeted agent for age-associated chronic diseases. Cell Cycle 2008; 7:1020-35.
20. Kai L, Samuel SK, Levenson AS. Resveratrol enhances p53 acetylation and apoptosis in prostate cancer by inhibiting MTA1/NuRD complex. Int J Cancer 2010; 126:1538-48.
21. Meeran SM, Ahmed A, Tollefsbol TO. Epigenetic targets of bioactive dietary components for cancer prevention and therapy. Clin Epigenetics 2010; 1:101-16.
22. Papoutsis AJ, Lamore SD, Wondrak GT, Selmin OI, Romagnolo DF. Resveratrol prevents epigenetic silencing of BRCA-1 by the aromatic hydrocarbon receptor in human breast cancer cells. J Nutr 2010; 140:1607-14.
23. Shakibaei M, Buhrmann C, Mobasheri A. Resveratrol-mediated SIRT-1 Interactions with p300 modulate receptor activator of NF{kappa}B ligand (RANKL) activation of NF{kappa}B signaling and inhibit osteoclastogenesis in bone-derived cells. J Biol Chem 2011; 286:11492-505.
24. Wakeling LA, Ions LJ, Ford D. Could Sirt1-mediated epigenetic effects contribute to the longevity response to dietary restriction and be mimicked by other dietary interventions? Age (Dordr) 2009; 31:327-41.
25. Dowling DK, Simmons LW. Reactive oxygen species as universal constraints in life-history evolution. Proc Biol Sci 2009; 276:1737-45.
26. Queen BL, Tollefsbol TO. Polyphenols and aging. Curr Aging Sci 2010; 3:34-42.
27. Pirola L, Frojdo S. Resveratrol: one molecule, many targets. IUBMB Life 2008; 60:323-32.
28. Baur JA, Sinclair DA. Therapeutic potential of resveratrol: the in vivo evidence. Nat Rev Drug Discov 2006; 5:493-506.
29. Piper MD, Bartke A. Diet and aging. Cell Metab 2008; 8:99-104.
30. Weindruch R, Walford R. The Retardation of Aging and Disease by Dietary Restriction. Springfield: Charles C. Thomas Publisher, 1988.
31. Howitz KT, Bitterman KJ, Cohen HY, Lamming DW, Lavu S, Wood JG, et al. Small molecule activators of sirtuins extend Saccharomyces cerevisiae lifespan. Nature 2003; 425:191-6.
32. Agarwal B, Baur JA. Resveratrol and life extension. Ann NY Acad Sci 2011; 1215:138-43.
33. Barger JL, Kayo T, Vann JM, Arias EB, Wang J, Hacker TA, et al. A low dose of dietary resveratrol partially mimics caloric restriction and retards aging parameters in mice. PLoS One 2008; 3:2264.
34. Dasgupta B, Milbrandt J. Resveratrol stimulates AMP kinase activity in neurons. Proc Natl Acad Sci USA 2007; 104:7217-22.
35. Lanzilli G, Fuggetta MP, Tricarico M, Cottarelli A, Serafino A, Falchetti R, et al. Resveratrol downregulates the growth and telomerase activity of breast cancer cells in vitro. Int J Oncol 2006; 28:641-8.
36. Pearson KJ, Baur JA, Lewis KN, Peshkin L, Price NL, Labinskyy N, et al. Resveratrol delays age-related deterioration and mimics transcriptional aspects of dietary restriction without extending life span. Cell Metab 2008; 8:157-68.
37. Uchiumi F, Watanabe T, Hasegawa S, Hoshi T, Higami Y, Tanuma S. The effect of resveratrol on the werner syndrome RecQ helicase gene and telomerase activity. Curr Aging Sci 2011; 4:1-7.
38. Xia L, Wang XX, Hu XS, Guo XG, Shang YP, Chen HJ, et al. Resveratrol reduces endothelial progenitor cells senescence through augmentation of telomerase activity by Akt-dependent mechanisms. Br J Pharmacol 2008; 155:387-94.
39. Um JH, Park SJ, Kang H, Yang S, Foretz M, McBurney MW, et al. AMP-activated protein kinasedeficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010; 59:554-63.
40. Kelly GS. A review of the sirtuin system, its clinical implications and the potential role of dietary activators like resveratrol: part 2. Altern Med Rev 2010; 15:313-28.
41. Finkel T, Deng CX, Mostoslavsky R. Recent progress in the biology and physiology of sirtuins. Nature 2009; 460:587-91.
42. Haigis MC, Guarente LP. Mammalian sirtuins- emerging roles in physiology, aging and calorie restriction. Genes Dev 2006; 20:2913-21.
43. Rodriguez RM, Fraga MF. Aging and cancer: are sirtuins the link? Future Oncol 2010; 6:905-15.
44. Kelly G. A review of the sirtuin system, its clinical implications and the potential role of dietary activators like resveratrol: part 1. Altern Med Rev 2010; 15:245-63.
45. Guarente L, Picard F. Calorie restriction-the SIR2 connection. Cell 2005; 120:473-82.
46. Chen D, Guarente L. SIR2: a potential target for calorie restriction mimetics. Trends Mol Med 2007; 13:64-71.
47. Boily G, Seifert EL, Bevilacqua L, He XH, Sabourin G, Estey C, et al. SirT1 regulates energy metabolism and response to caloric restriction in mice. PLoS One 2008; 3:1759.
48. Bordone L, Guarente L. Sirtuins and beta-cell function. Diabetes Obes Metab 2007; 9:23-7.
49. Palacios JA, Herranz D, De Bonis ML, Velasco S, Serrano M, Blasco MA. SIRT1 contributes to telomere maintenance and augments global homologous recombination. J Cell Biol 2010; 191:1299-313.
50. von Figura G, Hartmann D, Song Z, Rudolph KL. Role of telomere dysfunction in aging and its detection by biomarkers. J Mol Med 2009; 87:1165-71.
51. Rando TA. Stem cells, ageing and the quest for immortality. Nature 2006; 441:1080-6.
52. Sharpless NE, DePinho RA. How stem cells age and why this makes us grow old. Nat Rev Mol Cell Biol 2007; 8:703-13.
53. Calvanese V, Fraga MF. SirT1 brings stemness closer to cancer and aging. Aging (Albany NY) 2011; 3:162-7.
54. Calvanese V, Lara E, Suarez-Alvarez B, Abu Dawud R, Vazquez-Chantada M, Martinez-Chantar ML, et al. Sirtuin 1 regulation of developmental genes during differentiation of stem cells. Proc Natl Acad Sci USA 2010; 107:13736-41.
55. Zhang Y, Wang J, Chen G, Fan D, Deng M. Inhibition of Sirt1 promotes neural progenitors toward motoneuron differentiation from human embryonic stem cells. Biochem Biophys Res Commun 2011; 404:610-4.
56. Shankar S, Nall D, Tang SN, Meeker D, Passarini J, Sharma J, et al. Resveratrol inhibits pancreatic cancer stem cell characteristics in human and KrasG12D transgenic mice by inhibiting pluripotency maintaining factors and epithelial-mesenchymal transition. PLoS One 2011; 6:16530.
57. Mouchiroud L, Molin L, Dalliere N, Solari F. Life span extension by resveratrol, rapamycin and metformin: The promise of dietary restriction mimetics for an healthy aging. Biofactors 2010; 36:377-82.
58. Fulda S. Resveratrol and derivatives for the prevention and treatment of cancer. Drug Discov Today 2010; 15:757-65.
59. Signorelli P, Ghidoni R. Resveratrol as an anticancer nutrient: molecular basis, open questions and promises. J Nutr Biochem 2005; 16:449-66.
60. Jang M, Cai L, Udeani GO, Slowing KV, Thomas CF, Beecher CW, et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997; 275:218-20.
61. Athar M, Back JH, Tang X, Kim KH, Kopelovich L, Bickers DR, et al. Resveratrol: a review of preclinical studies for human cancer prevention. Toxicol Appl Pharmacol 2007; 224:274-83.
62. Boocock DJ, Faust GE, Patel KR, Schinas AM, Brown VA, Ducharme MP, et al. Phase I dose escalation pharmacokinetic study in healthy volunteers of resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 2007; 16:1246-52.
63. Lin HY, Tang HY, Davis FB, Davis PJ. Resveratrol and apoptosis. Ann NY Acad Sci 2011; 1215:79-88.
64. Shukla Y, Singh R. Resveratrol and cellular mechanisms of cancer prevention. Ann NY Acad Sci 2011; 1215:1-8.
65. Csiszar A. Anti-inflammatory effects of resveratrol: possible role in prevention of age-related cardiovascular disease. Ann NY Acad Sci 2011; 1215:117-22.
66. Deng CX. SIRT1, is it a tumor promoter or tumor suppressor? Int J Biol Sci 2009; 5:147-52.
67. Boily G, He XH, Pearce B, Jardine K, McBurney MW. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 2009; 28:2882-93.
68. Herranz D, Serrano M. SIRT1: recent lessons from mouse models. Nat Rev Cancer 2010; 10:819-23.
69. Spindler SR. Rapid and reversible induction of the longevity, anticancer and genomic effects of caloric restriction. Mech Ageing Dev 2005; 126:960-6.
70. Petrovski G, Gurusamy N, Das DK. Resveratrol in cardiovascular health and disease. Ann NY Acad Sci 2011; 1215:22-33.
71. Breitenstein A, Stein S, Holy EW, Camici GG, Lohmann C, Akhmedov A, et al. Sirt1 inhibition promotes in vivo arterial thrombosis and tissue factor expression in stimulated cells. Cardiovasc Res 2011; 89:464-72.
72. Park CE, Kim MJ, Lee JH, Min BI, Bae H, Choe W, et al. Resveratrol stimulates glucose transport in C2C12 myotubes by activating AMP-activated protein kinase. Exp Mol Med 2007; 39:222-9.
73. Sharma S, Misra CS, Arumugam S, Roy S, Shah V, Davis JA, et al. Antidiabetic activity of resveratrol, a known SIRT1 activator in a genetic model for type-2 diabetes. Phytother Res 2011; 25:67-73.
74. Szkudelski T, Szkudelska K. Anti-diabetic effects of resveratrol. Ann NY Acad Sci 2011; 1215:34-9.
75. Zang M, Xu S, Maitland-Toolan KA, Zuccollo A, Hou X, Jiang B, et al. Polyphenols stimulate AMPactivated protein kinase, lower lipids and inhibit accelerated atherosclerosis in diabetic LDL receptordeficient mice. Diabetes 2006; 55:2180-91.
76. Bastianetto S, Dumont Y, Duranton A, Vercauteren F, Breton L, Quirion R. Protective action of resveratrol in human skin: possible involvement of specific receptor binding sites. PLoS One 2010; 5:12935.
77. Bastin J, Lopes-Costa A, Djouadi F. Exposure to resveratrol triggers pharmacological correction of fatty acid utilization in human fatty acid oxidation-deficient fibroblasts. Hum Mol Genet 2011; 20:2048-57.
78. Elmali N, Baysal O, Harma A, Esenkaya I, Mizrak B. Effects of resveratrol in inflammatory arthritis. Inflammation 2007; 30:1-6.
79. Rayalam S, Della-Fera MA, Baile CA. Synergism between resveratrol and other phytochemicals: Implications for obesity and osteoporosis. Mol Nutr Food Res 2011; In press.
80. Docherty JJ, Smith JS, Fu MM, Stoner T, Booth T. Effect of topically applied resveratrol on cutaneous herpes simplex virus infections in hairless mice. Antiviral Res 2004; 61:19-26.
81. Karuppagounder SS, Pinto JT, Xu H, Chen HL, Beal MF, Gibson GE. Dietary supplementation with resveratrol reduces plaque pathology in a transgenic model of Alzheimer's disease. Neurochem Int 2009; 54:111-8.
82. Marambaud P, Zhao H, Davies P. Resveratrol promotes clearance of Alzheimer's disease amyloid-beta peptides. J Biol Chem 2005; 280:37377-82.
83. Gehm BD, McAndrews JM, Chien PY, Jameson JL. Resveratrol, a polyphenolic compound found in grapes and wine, is an agonist for the estrogen receptor. Proc Natl Acad Sci USA 1997; 94:14138-43.
84. Brown VA, Patel KR, Viskaduraki M, Crowell JA, Perloff M, Booth TD, et al. Repeat dose study of the cancer chemopreventive agent resveratrol in healthy volunteers: safety, pharmacokinetics and effect on the insulin-like growth factor axis. Cancer Res 2010; 70:9003-11.
85. Sandhu MS, Dunger DB, Giovannucci EL. Insulin, insulin-like growth factor-I (IGF-I), IGF binding proteins, their biologic interactions and colorectal cancer. J Natl Cancer Inst 2002; 94:972-80.
86. Patel KR, Scott E, Brown VA, Gescher AJ, Steward WP, Brown K. Clinical trials of resveratrol. Ann NY Acad Sci 2011; 1215:161-9.